In vivo, CD73 blockade and anti-CTLA-4 co-therapy enhanced CD8+ T-cell infiltration in a B16-F10 melanoma model and inhibited tumour growth.88 Similarly, in multiple in vivo solid tumour models, combining ACT with CD73 blockade, FasL blockade or endothelin B receptor inhibition led to enhanced T-cell homing and infiltration into tumours, resulting in tumour regression.36, 42. The gene discussed is FASLG; the disease is neoplasm.